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Vitamin E–loaded dialyzer resets PBMC-operated cytokine
network in dialysis patients.
Background. In hemodialysis patients the activity of stimu-
lated Th1 lymphocytes is depressed, while Th2 cells are con-
stitutively primed. Such phenomena may depend on monocyte
activation and altered release of interleukin (IL)-12 and IL-18,
which regulate Th cell differentiation. Reactive oxygen species
(ROS) activate monocytes; therefore, a hemodialyzer with
antioxidant activity would contrast ROS, prevent monocyte
activation, reset IL-12 and IL-18 release, and restore Th1/Th2
balance.
Methods. Ten patients on regular dialysis treatment (RDT)
with cellulosic membrane (CM) were shifted to vitamin
E–coated dialyzer (VE). During treatment with CM and af-
ter 3, 6, and 12 months of treatment with VE, peripheral blood
mononuclear cells (PBMC) and purified CD4+ cells were iso-
lated, and cultured, resting, mitogen-stimulated, and interferon
c (IFNc), IL-4, IL-10, IL-12, and IL-18 release was measured.
Vitamin E and A plasma levels and the effects of a single dialysis
session on peripheral blood NO levels were assayed.
Results. The constitutive release of IL-4 and IL-10 by CD4+
cells was abated significantly by treatment with VE (nadir -
77.8% and −55.3%, respectively, at 12 months). INFc release by
mitogen-stimulated CD4+ recovered with VE (zenith +501%
at 12 months). PBMC constitutive production of IL-12 and IL-
18 was significantly reduced by VE (nadir at 12 months −64.7%
and −51.3%, respectively). VE increased plasma levels of vita-
mins E and A. NO plasma levels fell after a single dialysis treat-
ment with VE (−17%, P < 0.05) in contrast with CU (+27.1%,
P < 0.05).
Conclusion. The network of cytokines released by monocytes
and Th cells is reset toward normality by treatment with vitamin
E–coated dialyzer.
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Patients with end-stage renal disease (ESRD) on reg-
ular dialysis treatment (RDT) have an impaired immune
defense that depends mainly on defective cell-mediated
response [1–2]. We have described [3] a novel aspect of
the immune dysfunction associated with RDT [i.e., an
imbalanced activity of the two T helper (Th) lymphocyte
subsets], which results in an overwhelming prevalence of
Th2 over Th1 cells. This imbalance leads to high constitu-
tive production of interleukin (IL)-4 and IL-10, and sup-
pression of interferon-c (IFN-c) (i.e., a configuration of
cytokine network that may play a pivotal role in causing
immunodeficiency) [4–7].
The reason(s) for the altered Th cell polarization asso-
ciated with hemodialysis is obscure. Hemodialysis causes
a rise in plasma levels of interleukin 2 receptor due to ab-
normal T-cell preactivation [8–10]; nonetheless, PBMC
of patients on RDT are unable to enhance IL-2 produc-
tion when stimulated [11]. Because IL-2 is a product of
Th1 lymphocytes, these findings suggest that RDT causes
a chronic activation of Th1 cells, and exhausts their ca-
pacity to respond to an acute challenge. The activation
and proliferation of Th1 lymphocytes are regulated by
macrophages/monocytes through the release of IL-12 and
IL-18 [12–17], two cytokines that induce the production of
IFN-c, the most powerful Th1 cell promoter. Hemodial-
ysis activates circulating mononuclear phagocytes so that
they release increased amounts of IL-12 [3, 18]. Thus,
the available evidence suggests that in patients on RDT,
repeated stimulation of monocytes is a determinant of
chronic priming of Th1 lymphocytes.
An effect of the contact of blood with biomaterials in
hemodialysis is the production of reactive oxygen species
(ROS) by monocytes and polymorphonuclear leuko-
cytes [19–20]. Interestingly, ROS amplify the phagocytic
capacity of monocytes [21], advanced oxidation prod-
ucts present in the plasma of patients on RDT are ca-
pable of triggering monocyte oxidative burst [19–21],
oxidized lipids activate monocytes [22], and the an-
tioxidant a-tocopherol decreases IL-1b release from
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activated human monocytes [23]. These findings point to
oxidative stress as a mechanism of monocyte activation
in hemodialysis.
a-Tocoferol is a powerful scavenger that protects
plasma molecules and cell membranes from peroxidative
damage [24–25]. To contrast the effects of ROS produced
during hemodialysis [26], a dialyzer has been developed
that consists of a multilayer cellulose membrane coated
with vitamin E on the blood surface [27]. Studies in vivo
have shown that short-term treatment with this dialyzer
increases vitamin E blood levels [19, 28] and affords pro-
tection against dialysis-induced oxidative stress [29–30].
In addition, the high IL-6 release from PBMC, a sign of
dialysis-induced monocyte activation [31–32], is reduced
by vitamin E–coated dialyzer [33].
Based on the aforesaid premises, the present study
tests the hypothesis that, by contrasting the oxidative
stress generated during dialysis, the a-tocoferol–bonded
dialyzer attenuates monocyte priming, and reduces the
release of cytokines IL-12 and IL-18. Should this hypoth-
esis hold, the vitamin E–loaded dialyzer might prevent
the chronic stimulation and exhaustion of Th1 cells driven
by monocytes, and would restore the capacity of Th1 cells
to respond to an acute challenge.
METHODS
Patients and controls
Ten patients (7 male, 3 female) aged 31–65, mean
52.4 ± 16.8 years, with end-stage renal disease were stud-
ied. The causes of renal failure were polycystic kidney dis-
ease (N = 2), chronic glomerulonephritis (N = 3), chronic
pyelonephritis (N = 1), interstitial nephritis (N = 1), and
nephroangiosclerosis (N = 3). The patients were on RDT
with non-reused dialyzers 4 hours thrice weekly. The di-
alytic procedure was a standard bicarbonate dialysis, and
the Kt/V index ranged from 1.22 to 1.34. The surface of
the filters was tailored to the needs of the patients, and
the patients were clinically stable throughout the study. In
particular, no relevant changes occurred in plasma levels
of urea, phosphate, calcium, and creatinine, or in hemat-
ocrit, Kt/V, and leukocyte counts. Patients with clinical or
humoral signs of infection, inflammation, or malignancy,
and diabetic patients were excluded from the study. No
patient was under treatment with drugs acting directly
on the immune system, such as steroids or other im-
munosuppressants, and none received drugs known as im-
munomodulators [e.g., calcitriol, angiotensin-converting
enzyme (ACE) inhibitors]. Calcitriol in particular was
stopped in all patients for at least six months before the
study, and serum calcium levels were maintained by oral
calcium supplementation.
The control group consisted of eight healthy volunteers
(3 male, 5 female) aged 24–48, mean 34.5 ± 11.7 years,
from our medical staff. All subjects gave informed con-
sent to the study.
Study design
The patients were studied while on RDT with cellulosic
dialyzer (cellulose acetate) for at least 12 consecutive
months (RDT-CM), then were shifted to dialysis with vi-
tamin E–loaded filter (Excebrane) (Terumo, Italy) and
studied again after 3, 6, and 12 months on the new treat-
ment (RDT-VE). Blood was collected from patients just
before starting the dialysis session and from controls af-
ter overnight fast. Part of the blood was used to isolate
and culture peripheral blood mononuclear cells (PBMC)
and purified CD4+ lymphocytes, and part was used to
measure plasma levels of vitamin E and A, and of nitric
oxide (NO). PBMC and CD4+ cells were cultured for
48 hours either in unstimulated condition or stimulated
with mitogens (see below), and cytokines (IFNc, IL-4, IL-
10, IL-12, IL-18) were measured in culture supernatant.
Cytokines prototypic of T- helper lymphocytes (INF-c,
IL-4, and IL-10) were measured in CD4+purified cell cul-
tures, while cytokines produced by monocytes (IL-12 and
IL-18) were measured in PBMC cultures; the latter pol-
icy was preferred rather than isolating monocytes from
PBMC because isolation procedures activate monocytes.
The way in which blood was collected and supernatants
were stored has been described in our previous studies
[34].
Isolation and culture of PBMC
PBMC were isolated by gradient centrifugation as we
described in a previous paper [35]. In brief, the cells
were aspirated from the interface, washed three times
in phosphate-buffered saline (PBS) (Life Technologies,
Milan, Italy), and resuspended at a cell density of 2 ×
106 cells/mL in RPMI 1640 medium (Life Technolo-
gies) containing 1% decomplemented fetal calf serum
(FCS) inactivated at 56◦C (Sigma-Aldrich, Milan, Italy),
2 mmol/L L-glutamine, 100 IU/mL penicillin (Life Tech-
nologies), and 100 lg/mL streptomycin (Life Technolo-
gies). After 48 hours of incubation at 37◦C in humidified
atmosphere containing 5% CO2, cell-free supernatants
were collected by centrifugation for 10 minutes at 400g,
passed through a millipore filter (0.2 l; Sigma-Aldrich),
and stored at −20◦C.
On average, PBMC contained 74% (range, 72%–77%)
lymphocytes and 26% (range, 22%–29%) monocytes.
The average fraction represented by lymphocytes was
similar in PBMC harvested from control patients (76%)
and RDT patients at the various steps of the study:
74% during treatment with the cellulosic membrane,
76%, 77%, and 75% after 3, 6, and 12 months, respec-
tively, of treatment with vitamin E–coated dialyzer. Cell
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viability, determined by Trypan blue dye exclusion test,
was >95%.
Purification and culture of CD4+ cells
T-helper lymphocytes were isolated from PBMC as we
previously described [3]. In brief, PBMC [107 cells in
80 lL of PBS buffer supplemented with 2 mmol/L EDTA
and 0.5% bovine serum albumin (BSA)] were incubated
for 10 minutes at 6 to 12◦C with a cocktail of hapten-
conjugated antibodies recognizing CD8, CD11b, CD19,
CD56, CD16, and CD36 (20 lL of cocktail solution/107
cells). After wash and resuspension in 80 lL of buffer, the
cells were incubated for 15 minutes at 6 to 12◦C with an
antihapten antibody coupled with magnetic microbeads
(MACS System; Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany). The procedure resulted in indirect
magnetization of non-Th cells (i.e., B cells, monocytes,
natural killer cells, CD8+ cells, granulocytes, basophils,
dendritic cells, early erythroid cells, and platelets). After
magnetization, PBMC were passed over a separation col-
umn (LS+) and placed in a strong magnetic field so that
the cells loaded with magnetic beads were retained in the
column. The purity of the isolated Th cells was analyzed
by flow cytometry (Epics Profile II; Coulter Immunology,
Miami, FL, USA) with monoclonal anti-CD3, anti-CD4,
and anti-CD8 antibodies. CD4+ cells averaged 95.9% ±
3.7%. Purified CD4+ cells were cultured at a cell density
of 5 × 105 cells/mL in the same medium as that used for
PBMC. After 48 hours of incubation at 37◦C in humidified
atmosphere containing 5% CO2, cell-free supernatants
were collected and stored at −20◦C.
Stimulation studies
In stimulation studies, PBMC were cultured for
48 hours in the presence of lipopolysaccharide (LPS,
10 lg/mL; Sigma-Aldrich), while CD4+ cells were cul-
tured for 48 hours in the presence of phytohemagglutinin
(PHA) (10 lg/mL).
Cytokine assay
Cytokines (IL-4, IL-10, IL-12 p70, IL-18, and IFNc)
were assessed by enzyme-linked immunosorbent assay
(ELISA) on cell-free supernatant. Antibody pairs were
used according to instructions of the supplier firms. IL-18
assay was performed with reagents obtained from R&D
Systems (Minneapolis, MN, USA) (primary, MoAb: clone
52713.11, 1 lg/mL; secondary, PolyAb 250 ng/mL); assay
sensitivity was 4.3 pg/mL. IFNc and IL-10 assays were
conducted with reagents purchased from Immunokon-
tact (Frankfurt am Main, Germany) as follows: IFNc:
primary, MoAb clone 43.11 at 5 lg/mL, and secondary,
PolyAb at 50 ng/mL (assay sensitivity 0.72 pg/mL); IL-10:
MoAb clone 9016.2 at 4 lg/mL, detecting MoAb clone
JES3-1248 at 50 ng/mL (assay sensitivity 1.6 pg/mL).
Bioactive p70 IL-12 assay was performed with reagents
supplied by Endogen (Woburn, MA, USA) as follows:
IL-12 MoAb clone 20C2 at 4 lg/mL, detecting MoAb
clone C8.6 at 1 lg/mL (assay sensitivity 2.5 pg/mL). Fi-
nally, IL-4 assay was performed with a commercially
available kit purchased from Endogen.
Plasma levels of vitamin E and vitamin A
Plasma levels of c- and a-tocoferol were measured by
high-performance liquid chromatography (HPLC) anal-
ysis as we previously described [36]. Plasma (200 lL) was
mixed with 200 lL of tocopherol acetate in methanol
(32.5 lg/mL) and extracted with 500 lL of hexane. The
organic solvent recovered after centrifugation was dried
with nitrogen and resuspended in 400 lL of HPLC
grade methanol. The samples were then analyzed with
a Jasco HPLC system (Jasco Corporation, Tokyo, Japan)
equipped with an UV detector. The mobile phase was
98% methanol + 2% HPLC grade water, and the flow
rate was 1.6 mL/min. Extracted samples (100 lL) were
injected onto an ALLTIMA C18 5 lm, 250 mm × 4.6 mm
inner dimension (i.d.) column (ALLTECH, Italia), pre-
ceded by an ALLTECH 7.5 × 4.6 mm i.d. All-guardTM
Cartridge Holder. The UV detector was set at 325 nm for
7 minutes and 292 nm to end of run, and data were col-
lected and analyzed with the software Borwin 1.5 (Jasco
Corporation). Solvents for sample extractions and the
main chemicals used were from Sigma (Steinheim,
Germany) or Merck (Darmstadt, Germany). HPLC
grade solutions were from Carlo Erba (Milano, Italy).
Total nitric oxide (NOx) assay
We investigated the effects of a single dialysis on NO
levels in peripheral blood (i.e., in blood sampled from
arterial dialysis line at the start and the end of dialysis
session). In addition, we investigated the effect of blood
passage through the filter on NO plasma levels. To this
purpose we obtained simultaneous blood samples from
arterial and venous dialysis lines 60 minutes after starting
dialysis session. We measured NO by photometric analy-
sis with a nitrate/nitrite colorimetric assay kit (R&D Sys-
tems). Nitric oxide production was determined as NO2 +
NO3 (NOx) with the Griess reagent after reduction of
nitrate to nitrite with nitrate reductase. Readings were
at 540 nm, and baseline correction was carried out at
620 nm. The sensitivity limit of the assay was 1.35 lmol/L.
Statistical analysis
All data are expressed as mean ± standard de-
viation (SD). Statistical analysis was carried out by
repeated measures analysis of variance (ANOVA) anal-
ysis followed by Bonferroni’s multiple comparison test
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Table 1. Plasma levels of vitamin E and vitamin A in control subjects (CON) and in patients on RDT
CON RDT-CM RDT-VE 3m RDT-VE 6m RDT-VE 12m
Vit E lmol/L 30.7 ± 7.5 26.1 ± 10.3 32.3 ± 12.7a 34.7 ± 14.7a 35.0 ± 15.1a
Vit A lmol/L 3.75 ± 0.87 3.39 ± 1.60 4.23 ± 1.49a 4.40 ± 4.46a 3.72 ± 0.79
Vit E, vitamin E; Vit A, vitamin A. Data are mean ± SD. Patients were treated with cellulosic membrane (RDT-CM), or Vitamin E-coated filter (RDT-VE) for 3
months (3m), 6 months (6m), and 12 months (12m).
aP < 0.05 vs. RDT-CM.
Table 2. Plasma levels of NOx (lmol/L) in control subjects (Con) and in patients on RDT treated with cellulosic membrane (RDT-CM) or
vitamin E–coated filter (RDT-VE)
Pre Post (A) (V)
CON 42.8 ± 17.3 – – –
RDT-CM 100.7 ± 39.9a 128 ± 45.5c 126 ± 40.3 137.5 ± 44.4
RDT-VE 69.6 ± 31.2a,b 57.8 ± 20.3b,c 67.5 ± 23.9b 49.5 ± 18.7b,d
Pre and Post refer to peripheral blood (i.e., blood sampled from the arterial dialysis line) at the start and the end of the dialysis session. A and V refer to blood sampled
from the arterial (A) or venous (V) dialysis line 60 minutes after starting the dialysis session. Data are mean ± SD.
aP < 0.05 vs. Con.
bP < 0.05 vs. RDT-CM.
cP < 0.05 vs. Pre.
dP < 0.05 vs. (A).
(STATVIEW software for the Macintosh; Cary, NC,
USA); differences were estimated significant at P values
<0.05.
RESULTS
Circulating levels of antioxidant vitamins
Table 1 shows levels of vitamins E and A in plasma of
patients on RDT sampled just before starting the dial-
ysis session. Levels of vitamin E were increased after
3 months of treatment with the vitamin E–loaded dia-
lyzer and remained high throughout the rest of the study.
Levels of vitamin A were increased significantly after 3
and 6 months of treatment.
Plasma nitric oxide
Data are shown in Table 2. NOx levels in peripheral
blood sampled before starting dialysis session were sig-
nificantly higher in dialysis patients, either RDT-CM or
RDT-VE, than in normal volunteers. Peripheral blood
NOx levels increased at the end of dialysis with cellulose
filter, while at the end of dialysis with vitamin E–loaded
filter they decreased, becoming similar to levels in normal
volunteers. Passage of blood through vitamin E–loaded
filter caused a significant decrease in NOx levels.
Release of IFNc, IL-4, and IL-10 by CD4+ cells
Figure 1 shows the release of IFNc by unstimulated and
PHA-stimulated cells. The release of IFN-c was similarly
low in unstimulated control cells as in cells of patients on
dialysis, either RDT-CM or RDT-VE. PHA increased the
release of IFN-c in all cells, but the response to PHA was
about 10-fold lower in RDT-CM than in control patients
(89.9 ± 18.2 pg/5 × 105 cells vs. 838.4 ± 142.7, respectively,
P < 0.001). A significant recovery of IFN-c release by
CD4+ cells of dialysis patients occurred after treatment
with vitamin E–loaded filter (in pg/5 × 105 CD4+ cells:
402.6 ± 78.6 at 3 months, 509.5 ± 76.1 at 6 months, and
540.8 ± 106.3 at 12 months, all P < 0.05 vs. RDT-CM).
The release of IL-4 by CD4+ cells is shown in
Figure 2. Unstimulated control patients produced sig-
nificantly less IL-4 than unstimulated RDT-CM (3.3 ±
0.62 pg/5 × 105 cells vs. 61.0 ± 13.4, respectively, P <
0.01). The excess constitutive production of IL-4 asso-
ciated with cellulose dialysis was significantly attenuated
by treatment with vitamin E–loaded dialyzer; IL-4 release
decreased to 17.1 ± 4.7 pg/5 × 105 cells at 3 months, 16.3 ±
6.0 pg/5×105 cells at 6 months, and 13.5±2.2 pg/5×105 at
12 months, all P < 0.05 versus RDT-CM. Stimulation with
PHA strikingly increased IL-4 release in control patients
(87.5±21.6 pg/5×105 CD4+, P <0.01) but did not raise it
further in RDT-CM. In other words, RDT-CM behaved as
if they were prestimulated. In fact, a significant response
to stimulation was restored after treatment with vitamin
E–loaded dialyzer (i.e., after the spontaneous production
of IL-4 was lowered).
The release of IL-10 by CD4+ cells is shown in Figure 3.
Unstimulated control patients produced significantly less
IL-10 than cells of dialysis patients, either treated with
cellulose, or with vitamin–E coated dialyzer. However,
the excess spontaneous production of IL-10 in RDT-CM
(144.7 ± 37.4 pg/5 × 105 cells) was significantly reduced
by shifting patients from cuellulose to vitamin E–coated
dialyzer (82.5 ± 27.2 pg/5 × 105 cells at 3 months, 67.7 ±
16.8 pg/5×105 cells at 6 months, and 64.7±13.5 pg/5×105
cells at 12 months, all P < 0.05 vs. RDT-CM). Stimulation
raised IL-10 production in all cells, but control patients
attained higher levels than RDT (all groups).
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Fig. 1. Interferon c (IFNc) production by
CD4+ of normal subjects (Con), and patients
on regular hemodialysis treatment with cel-
lulosic membranes (RDT-CM) and vitamin
E–coated membranes (RDT-VE) at 3, 6, and
12 months (3m, 6m, and 12 m) of therapy.
∗Indicates a significant difference between
stimulated phytohemagglutinin (PHA+) and
unstimulated (PHA−) cells of the same group
(P < 0.001 Con; P < 0.01 RDT-VE 3m, RDT-
VE 6m and RDT-VE 12m; P < 0.05 RDT-
CM). ◦ Indicates a significant difference vs.
stimulated cells of Con (P < 0.01 RDT-CM;
P < 0.05 all RDT-VE). ◦◦P < 0.05 vs. stimu-
lated RDT-CM.
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Fig. 2. Interleukin (IL)-4 production by
CD4+ of normal subjects (Con), and patients
on regular hemodialysis treatment with cel-
lulosic membranes (RDT-CM) and vitamin
E–coated membranes (RDT-VE) at 3, 6, and
12 months of therapy. ∗Indicates a significant
difference between stimulated phytohemag-
glutinin (PHA+) and unstimulated (PHA−)
cells of the same group (P < 0.001 Con; P <
0.05 all RDT-VE). ◦ Indicates a significant dif-
ference vs. unstimulated cells of Con (P < 0.02
RDT-CM; P < 0.05 all RDT-VE). ∗∗P < 0.05
vs. unstimulated RDT-CM.
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Fig. 3. Interleukin (IL)-10 production by
CD4+ of normal subjects (Con), and patients
on regular hemodialysis treatment with cellu-
losic membranes (RDT-CM) and vitamin E–
coated membranes (RDT-VE) at 3, 6, and 12
months of therapy. ∗Indicates a significant dif-
ference between stimulated (PHA+) and un-
stimulated (PHA−) cells of the same group
(P < 0.001 Con; P < 0.05 all RDT). ◦P < 0.03
vs. unstimulated cells of Con. ∗∗P < 0.05 vs.
unstimulated RDT-CM.
Release of IL-12 and IL-18 by PBMC
The release of IL-12 by PBMC is shown in Figure 4.
Unstimulated control patients produced significantly less
IL-12 than all unstimulated RDT. However, the excess
spontaneous production of IL-12 was significantly atten-
uated by shifting patients from cellulose to vitamin E–
loaded dialyzer (RDT-CM: 54.0 ± 17.7 pg/2 × 106 PBMC;
RDT-VE at 3 months: 21.7 ± 7.0 pg/2 × 106 PBMC;
1478 Libetta et al: Vitamin E–loaded dialyzer resets cytokine network in dialysis patients
0
50
100
150
200
250
400
350
300
IL
-1
2,
 p
g/
2 
×
 1
06
 
PB
M
C
Con RDT-CM RDT-VE3m RDT-VE6m RDT-VE12m
LPS–
LPS+
*
**
****
*
*
*
*
Fig. 4. Interleukin (IL)-12 production by pe-
ripheral blood mononuclear cells (PBMC)
of normal subjects (Con), and patients on
regular hemodialysis treatment with cellu-
losic membranes (RDT-CM) and vitamin E–
coated membranes (RDT-VE) at 3, 6, and
12 months of therapy. ∗Indicates a significant
difference between stimulated phytohemag-
glutinin (PHA+) and unstimulated (PHA−)
cells of the same group (P < 0.001 Con; P <
0.03 all RDT-VE). ◦Indicates a significant dif-
ference vs. unstimulated cells of Con (P < 0.01
RDT-CM; P < 0.05 all RDT-VE). ∗∗P < 0.05
vs. unstimulated RDT-CM. ◦◦Indicates a sig-
nificant difference vs. stimulated cells of Con
(P < 0.01 RDT-CM; P < 0.05 all RDT-VE).
P < 0.05 vs. stimulated RDT-VE.
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Fig. 5. Interleukin (IL)-18 production by pe-
ripheral blood mononuclear cells (PBMC)
of normal subjects (Con), and patients on
regular hemodialysis treatment with cellu-
losic membranes (RDT-CM) and vitamin E–
coated membranes (RDT-VE) at 3, 6, and
12 months of therapy. ∗Indicates a significant
difference between stimulated phytohemag-
glutinin (PHA+) and unstimulated (PHA−)
cells of the same group (P < 0.001 Con; P
< 0.05 all RDT-VE). ◦ Indicates a significant
difference vs. unstimulated cells of Con (P <
0.01 RDT-CM; P < 0.02 all RDT-VE). ∗∗P
< 0.05 vs. unstimulated RDT-CM. ◦◦Indicates
a significant difference vs. stimulated cells of
Con (P < 0.04). P < 0.05 vs. stimulated RDT-
VE6m and RDT-VE12m.
RDT-VE at 6 months: 18.1 ± 4.3 pg/2 × 106 PBMC; RDT-
VE at 12 months: 19.1 ± 3.7 pg/2 × 106 PBMC). Stimu-
lation with LPS significantly raised IL-12 production in
control patients but not in RDT-CM. In contrast with the
unresponsiveness of RDT-CM, stimulated RDT-VE were
able to significantly increase IL-12 production, a result of
two effects of treatment with vitamin E–coated dialyzer
(i.e., the decreased unstimulated release combined with
the increased stimulated release).
The release of IL-18 by PBMC is shown in Figure 5.
The behavior of IL-18 replicates that of IL-12. Cellulose
dialysis was associated with a more than 30-fold excess
spontaneous release of IL-18 and unresponsivenes to
stimulation. Vitamin E–loaded dialyzer significantly re-
duced the spontaneous production of IL-18 (from 167.5 ±
33.5 pg/2 × 106 PBMC in RDT-CM to 102.7 ± 16.9 pg/2 ×
106 PBMC in RDT-VE at 3 months, 90.1 ± 16.9 pg/2 ×
106 PBMC in RDT-VE at 6 months, and 81.7 ± 17.3 pg/2
× 106 PBMC in RDT-VE at 12 months), and raised the
stimulated production of the cytokine, thus restoring a
significant response of PBMC to LPS.
IFNc/IL-4 ratio
The ratio between the amounts of IFNc and IL-4 re-
leased by CD4+ cells (an index of Th1/Th2 cell balance)
is shown in Figure 6. The ratio was significantly higher in
control patients than in RDT-CM, both in the unstim-
ulated state (1.08 ± 0.24 vs. 0.08 ± 0.03, respectively,
P < 0.01), and after stimulation with PHA (9.7 ± 2.7 vs.
1.34 ± 0.45, respectively, P < 0.01). Treatment with
vitamin E–loaded dialyzer increased significantly the
IFNc/IL-4 ratio, both in unstimulated cells (0.24 ± 0.11
at 3 months, 0.24 ± 0.12 at 6 months, and 0.25 ± 0.08 at
12 months) and in stimulated cells (6.3 ± 2.2 at 3 months,
8.5 ± 3.4 at 6 months, and 8.1 ± 1.7 at 12 months). In
fact, after 6 and 12 months of treatment with vitamin E–
loaded dialyzer the IFNc/IL-4 ratio was not different in
stimulated control patients and RDT-VE.
DISCUSSION
The results of this study confirm and extend our
previous observation that treatment with cellulose
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Fig. 6. Interferon (IFN)c/interleukin (IL)-4
ratio of normal subjects (Con), and patients
on regular hemodialysis treatment with cellu-
losic membranes (RDT-CM) and vitamin E–
coated membranes (RDT-VE) at 3, 6, and 12
months of therapy. ◦ Indicates a significant dif-
ference vs. unstimulated cells of Con (P < 0.01
RDT-CM; P < 0.05 all RDT-VE). ∗Indicates
a significant difference vs. stimulated cells of
Con (P < 0.01 RDT-CM; P < 0.05 all RDT-
VE3m).
dialyzer is associated with a dysregulation of the
mononuclear cell-operated cytokine network. Such dys-
regulation encompasses the following phenomena: (1)
PBMC spontaneously produce supranormal amounts of
IL-12 and IL-18; (2) LPS-stimulated PBMC cannot fur-
ther increase the release of IL-12 and IL-18, and cannot
achieve production rates as high as those attained by stim-
ulated normal cells; (3) Th lymphocytes spontaneously
produce supranormal amounts of IL-4 and IL-10. The
constitutive production of IL-4 is particularly impressive
because it equals the production of PHA-stimulated nor-
mal cells, and represents an apparent ceiling that cannot
be further increased by stimulation with mitogen; and (4)
Th lymphocytes stimulated with PHA produce much less
INFc than stimulated control cells.
These observations support two conclusions. The first
is that dialysis with cellulose activates circulating mono-
cytes, as indicated by the spontaneous overproduction
of IL-12 and IL-18 by PBMC. The finding that LPS-
stimulated PBMC cannot further increase the release of
IL-12 and IL-18 is consistent with a state of continued
stimulation, resulting in loss of reactivity to an acute chal-
lenge [30]. The second is that dialysis with cellulosic mem-
brane is associated with an overwhelming prevalence of
Th2 over Th1 cells, as indicated by the striking amount
of IL-4 (the prototypic Th2 cytokine) produced by un-
stimulated Th cells, and by the suppression of IFNc re-
lease (the prototypic Th1 cytokine) in PHA-stimulated
Th cells. The functional imbalance between the two Th
subsets is also witnessed by the high constitutive release
of IL-10, another Th2-related cytokine.
The prevalence of Th2 lymphocytes in a setting in which
PBMC produce increased amounts of IL-12 and IL-18
(i.e., two cytokines that stimulate the production of IFNc
and drive the differentiation of Th cells to the Th1 phe-
notype) [13, 15] is intriguing. We suggest that the two
phenomena are causally related (i.e., that the default of
Th1 cells results from their continued stimulation), even-
tually causing functional exhaustion [31]. In summary,
our findings delineate a sequence of events that starts
with activation of monocytes provoked by bioincompat-
ible membranes, and proceeds with release of IL-12 and
IL-18, recruitment of Th1 cells, exhaustion of Th1 cell
function, loss of the inhibitory control of Th1 on Th2 cells,
and eventual prevalence of Th2 cells [3].
Based on the evidence that oxidative stress generated
by dialysis is a leading cause of monocyte activation [19–
21], and assuming that monocyte activation sparks the dis-
turbance of cytokine network [37–39], we supposed that
treatment with a vitamin E–coated dialyzer might cor-
rect the altered cytokine production. The results of this
study seem to support this hypothesis. In fact, treatment
with vitamin E–loaded dialyzer significantly lowered the
spontaneous release of IL-12 and IL-18 by PBMC, and
restored the ability of PBMC to increase IL-12 and IL-
18 production in response to stimulation. In addition,
vitamin E–coated dialyzer caused a fall in constitutive
release of IL-4 and IL-10 by Th lymphocytes and sig-
nificantly raised IFNc production by stimulated Th cells.
It is reasonable to hold that these effects of vitamin E–
loaded dialyzer were the consequence of the antioxidant
property of vitamin E [19]. In fact, vitamin E–loaded
dialyzer is a dialyzer with a cellulose backbone, whose
unique differential trait is its vitamin E coat. In addition,
we showed that treatment with vitamin E–loaded dia-
lyzer was associated with a consistent increase in plasma
levels of vitamin E. Furthermore, serum levels of nitric
oxide, a representative member of the ROS family [20],
fell at the passage of blood through vitamin E–loaded
dialyzer, while it increased at the passage through the
cellulosic filter, and peripheral blood levels of NO were
significantly reduced by a dialysis session with vitamin E–
coated filter, but not with cellulosic dialyzer. Free radicals
produced during hemodialysis have very short half-lives
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and exhaust almost completely during passage of blood
through the filter [19]. Therefore, the local availability of
abundant vitamin E anchored to dialysis membrane may
have been particularly effective in contrasting dialysis-
generated ROS. However, the interdialytic increase in
plasma levels of vitamin E and A caused by treatment
with vitamin E–loaded dialyzer may have contributed to
contrast oxidative stress. In fact, oral supplementation of
vitamin E has been shown to reduce lipid peroxidation
and to increase LDL resistance to ex vivo oxidation in
uremic patients [40]. However, peroral administration of
vitamin E provides less effective antioxidant defense that
vitamin E–dialyzer in hemodialysis patients [41].
The partial reset of PBMC-operated cytokine network
caused by vitamin E–loaded dialyzer represents a sig-
nificant improvement of mononuclear cell function, not
the achievment of full normality. Possibly, the incomplete
normalization of PBMC activity depended on too short
a period of use of vitamin E–coated filter. However, the
benefit induced by vitamin E–loaded dialyzer was ap-
parent in three months, and no further improvement oc-
curred in the next nine months of treatment. In addition,
we have shown that a disturbance of PBMC-operated cy-
tokine network, characterized by increased spontaneous
production of IL-4 and attenuated mitogen-induced IFN-
c release, is present in patients with chronic renal failure
on conservative treatment [3]. Therefore, in uremic pa-
tients there exist mechanisms that alter PBMC activity,
independent of the insult caused by dialysis with bioin-
compatible cellulose, on which vitamin E–coated filter
may not be influent.
CONCLUSION
This study demonstrates that treatment with vita-
min E–coated dialyzer improves the defect of PBMC
function associated with cellulosic dialyzer consisting of
altered spontaneous and mitogen-stimulated cytokine re-
lease. The effects of vitamin E–coated filter, in particular
the recovery of reactive INFc production by Th1 cells and
the restriction of spontaneous IL-4 release by Th2 cells,
may have clinical importance. In fact, the inhibition of
Th1 cytokines and the prevalence of Th2 over Th1 lym-
phocytes may play a major role in impairing cell-mediated
immunity and phagocytic activity in patients on regular
hemodialysis treatment.
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